Our Mission is to develop simple, improved percutaneous transluminal angioplasty (PTA) technologies that improve the safety and economics of leg revascularization procedures.
Summa’s novel angioplasty balloon facilitates angioplasty procedures, allowing the procedure to be done with fewer steps and less equipment, which saves time, radiation to the patient and operator, and contrast dose to the patient.
There are two issued patents and FDA 510(k) clearance for marketing in the U.S.
Timothy Murphy, M.D.
Chief Executive Officer
Timothy P. Murphy, M.D. has spent the past 25 years as a clinician and clinical researcher in the field of interventional radiology. He was most recently an interventional radiologist at Rhode Island Hospital and a Full Professor, Research Track, in the department of Diagnostic Imaging at Alpert School of Medicine at Brown University.
He has served in various leadership roles at the Society of lnterventional Radiology (SIR), the largest interventional radiology society in the world, including President of the Society in 2011-2012. He served on the operations and steering committees of three of the most important NIH-sponsored clinical trials in vascular disease: CORAL, CLEVER, and ATTRACT, and has published over 200 journal articles and given more than 185 presentations all over the world.
Dr. Murphy has also been a leading medical device innovator serving as a consultant to Abbott Laboratories, Guidant, Genentech, Bayer and Terumo, and holding patents or patents-pending for several medical devices and treatment methods.
Dr. Murphy completed his radiology residency as well as his vascular and interventional radiology fellowship at Brown University School of Medicine’s Rhode Island Hospital. He received his B.A. and M.D., cum laude, from Boston University and received an honorary M.A. degree from Brown University.
Chief Operating Officer
Ms. Hobbs is an entrepreneurial medical device professional with over 20 years of industry experience in business development, general management, sales, marketing and training in the medical device and biotech sectors.
She currently serves as the Co-Chair of the Emergency Medicine Advisory Board at Brigham and Women’s Hospital. Danielle was most recently the Vice President of Marketing and Communications at ImmunSYS, Inc., a combination device/drug cancer therapy company. In 2013 she co-founded Capture Vascular, Inc. and served as its CEO until 2015. Capture is a medical device company that is developing a platform technology for thrombectomy and embolic protection in clot removal procedures.
Earlier in her career in 2005, Danielle founded and still operates Medevixx, a consulting firm that provides a range of business development, training and marketing solutions for numerous medical device and biotech companies in several therapeutic areas, including interventional radiology, interventional oncology, interventional cardiology and vascular surgery.
Danielle attended Ohio University on a basketball scholarship where she received a B.S. in Physiology with a Pre-Med concentration.
Medical Advisory Board
Gary Ansel, M.D.
Dr. Ansel is an internationally renowned interventional expert, both in peripheral vascular and cardiovascular procedures. He serves as an invited faculty member at many of the largest cardiovascular conferences and medical meetings all over the world.
Dr. Ansel currently serves as System Medical Chief, Vascular Program – OhioHealth and is the Associate Medical Director of the OhioHealth Research and Innovation Institute in Columbus, Ohio. He is an Assistant Clinical Professor of Medicine in the Department of Internal Medicine at the University of Toledo Medical Center, Toledo, Ohio.
Dr. Ansel has served as a primary investigator for numerous national and international research trials helping to develop improved patient care to those suffering with peripheral and cardiovascular disease. Dr. Ansel is a founding board member of the Vascular InterVentional Advances Conference (VIVA) which is a non-profit organization dedicated to the education and research of vascular disease.
Dr. Ansel received his medical degree from The Ohio State University College of Medicine where he also completed a postgraduate research fellowship in cardiology. He completed his residency and internship at the University of Toledo and received his post-fellowship training in peripheral vascular intervention at the Ochsner Clinic in New Orleans.
Dr. Ansel is affiliated with OhioHealth Heart and Vascular Physicians in Columbus, Ohio. He is a former member of the Peripheral Vascular Committee for the American College of Cardiology and continues to serve as a member of several professional societies. Dr. Ansel has served on the editorial board for Catheter and Cardiovascular Intervention, Cardiovascular Revascularization Medicine, Annals of Vascular Surgery, and Endovascular Today. He has contributed to journals such as The New England Journal of Medicine, Circulation, Journal of Endovascular Therapy, and The American Journal of Cardiology and has authored many medical book chapters.
James F. Benenati, M.D.
James F. Benenati, M.D., FSIR, is a practicing Interventional Radiologist, Medical Director, Noninvasive Vascular Laboratory and Fellowship Program Director at the Miami Cardiac & Vascular Institute at Baptist Hospital in Miami, Florida.
He is a Clinical Professor of Radiology at Florida International University College of Medicine and Collaborative Professor of Radiology at the University of South Florida College of Medicine. He is past President of SIR. He served as President of the Vascular Division for the Intersocietal Accreditation Committee (IAC) and served for over a decade on their board. He served as the annual meeting chairman for SIR in 2005. He was the recipient of the SIR Charles T. Dotter Award in 2014.
He has participated in numerous clinical research projects and national trials. His interest include peripheral arterial disease, abdominal aortic aneurysm and management of pulmonary embolism. He has authored and co-authored more than 100 scientific publications. He has been a Program Director of ISET for over 20 years.
He attended the University of Notre Dame as an undergraduate, received his medical degree from the University of South Florida College of Medicine, completed a residency in Diagnostic Radiology at Indiana University and a fellowship at Johns Hopkins.
Robert Lookstein, M.D.
Robert A Lookstein, MD MHCDL FSIR FAHA FSVM is Professor of Radiology and Surgery at the Icahn School of Medicine at Mount Sinai (ISMMS). After attending medical school at the State University of NY (SUNY) Health Science Center at Brooklyn in 1995, he completed his radiology residency and fellowship in Vascular and Interventional Radiology at ISMMS in New York. He subsequently joined the Division of Vascular and Interventional Radiology as Faculty in 2002.
Dr. Lookstein currently lectures around the world on various subjects in the field of Vascular and Interventional Radiology including peripheral arterial imaging and intervention, endovascular interventions, aortic stent-grafts, and deep vein thrombosis. He is recognized as an innovator in the field of peripheral vascular disease and noninvasive vascular imaging. His clinical practice is focused on the diagnosis and treatment of peripheral vascular disease.
Dr. Lookstein currently serves as Executive Vice Chairman in The Department of Diagnostic, Molecular, and Interventional Radiology for the Mount Sinai Health System. He previously served as System Vice Chair for Interventional Services as well as Division Chief of Vascular and Interventional Radiology.
Dr. Lookstein is currently involved in numerous research studies related to peripheral vascular disease including the VENITI VICI venous stent trial, the SAVAL study evaluating drug coated stents in the lower leg arteries, the PRESERVE
registry evaluating the safety and efficacy of Inferior Vena Cava filters, as well as the NHLBI funded BEST-CLI evaluating the role of endovascular revascularization for critical limb ischemia.Dr. Lookstein has authored hundreds of scientific abstracts and manuscripts related to cardiovascular imaging and intervention and has served as Assistant Editor for the American Journal of Roentgenology.
He is a regular faculty member of numerous national and international meetings including The International Society of Endovascular Therapy, Advanced Interventional Management, The Society of Interventional Radiology Annual Scientific Meeting, The Radiologic Society of North America, and The American Heart Association Scientific Sessions, and Vascular Interventional Advances (VIVA).
He is the Course Program Director of several national education courses including Lower Extremity Arterial Revascularization (LEARN), TransRadial EndovAscular Therapy (TREAT), Transcatheter Cardiovascular Therapeutics (TCT), and LINC Mount Sinai.
Dr. Lookstein serves on numerous committees within the Mount Sinai Health System related to patient safety and quality, novel procedure oversight, cardiovascular disease intervention value analysis, and performance improvement.
Rahul S. Patel, M.D. FSIR
Rahul S. Patel, MD FSIR is Assistant Professor of Radiology and Surgery at the Icahn School of Medicine at Mount Sinai (ISMMS). After attending medical at the University of Miami in 2002, he completed his residency in Diagnostic Radiology at Jackson Memorial Hospital in Miami, Florida. He then finished his fellowship in Vascular and Interventional Radiology at the Baptist and Cardiovascular Institute also in Miami, Florida in 2008. He joined the division of Vascular and Interventional Radiology at ISSM in 2012 after spending time as faculty at University of Maryland School of Medicine.
Dr. Patel is currently involved in numerous research studies related to peripheral vascular disease, interventional oncology, portal hypertension and complex porto-mesenteric thrombosis, and bariatric embolization.
Dr. Patel has published over 170 scientific abstracts and manuscripts related to cardiovascular imaging, peripheral vascular disease, interventional oncology, portal hypertension, and peripheral embolization.
He is a regular faulty member of numerous national meetings including the International Society of Endovascular Therapy, Advanced Interventional Management, The Society of Interventional Radiology Annual Scientific Meeting, The Radiologic Society of North America, and The American Heart Association Scientific Sessions, Transcatheter Cardiovascular Therapeutics (TCT), LINC Mount Sinai, and Vascular Interventional Advances (VIVA). He is also the course program director for TransRadial EndoVascular Therapy (TREAT).
Kenneth Rosenfield, M.D., MHCDS, MSCAI, FACC, FAHA
Dr. Rosenfield is an interventional cardiologist and vascular specialist performing complex cardiac and vascular interventions. He is Section Head for Vascular Medicine and Intervention in the Division of Cardiology at Massachusetts General Hospital. He earned a masters degree in Health Care Delivery Science from Dartmouth College.
In addition to being a master clinician and interventionalist, Dr. Rosenfield has dedicated much of his career to educating fellows, residents, students, and colleagues. He is the recipient of the distinguished Laennec award for his outstanding teaching and mentorship.
He is also a researcher and clinical trialist. He designed and served as national principle investigator for several landmark studies, including Aspire 2, Levant 2, Superb, ACT 1, and NIH BEST-CLI trial.
He is a leader in the cardiovascular world, having been elected to the Board of Governors of American College of Cardiology, immediate past-President of the MA ACC Chapter, and immediate past-President of the Society for Cardiovascular Angiography and Interventions (SCAI). Dr. Rosenfield is a founding member of VIVA, a 501c3 organization, and sits on its board of directors.
At Massachusetts General Hospital, he is the Medical director of the PERT Program, which he founded with his colleagues; he also founded the National PERT Consortium, a 501c3 organization dedicated to improving management, outcomes, and awareness of Pulmonary Embolism, and he served as its initial President; he remains a member of the PERT Consortium Executive Committee.
He recently has developed an innovative Balloon Pulmonary Angioplasty (BPA) program for patients with CTEPH at MGH, and is collaborating to develop a national initiative and database for these procedures.